Noxxon Pharma AG, which is developing oligonucleotides called Spiegelmers that can be engineered to bind to biological targets, has appointed Matthias Baumann as chief medical officer and a member of the management board of the company. Previously Dr Baumann was managing director and chief scientific officer of Focus Clinical Drug Development, a clinical research organisation. He has also held a number of positions in preclinical and clinical development positions with Hoffmann La Roche and Boehringer Mannheim.
Copyright 2011 Evernow Publishing Ltd